October 26, 2020 -- NBE Therapeutics has commenced a clinical study of its lead drug candidate, NBE-002, targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), for triple-negative breast cancer.
The trial is a global phase I/II, open-label study that will evaluate the recommended dose for safety and immunogenicity of the novel anti-ROR1 antibody-drug conjugate in patients with advanced solid tumors. The initial results from the study are expected in 2021.
NBE-002 was developed on the company's immunestimulatory antibody-drug conjugate (iADC) platform, which creates highly potent, immunostimulatory antibody-drug conjugates with a novel anthracycline payload. The lead candidate, NBE-002, has been demonstrated as safe and tolerable during preclinical development. It targets ROR1, a cell-surface protein that is expressed in malignant tissues across a broad variety of cancer types, including solid tumors.